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ABSTRACT: Visceral leishmaniasis (VL), caused by the
protozoan parasites Leishmania donovani and L. infantum, is
responsible for ∼30 000 deaths annually. Available treatments
are inadequate, and there is a pressing need for new
therapeutics. N-Myristoyltransferase (NMT) remains one of
the few genetically validated drug targets in these parasites.
Here, we sought to pharmacologically validate this enzyme in
Leishmania. A focused set of 1600 pyrazolyl sulfonamide
compounds was screened against L. major NMT in a robust
high-throughput biochemical assay. Several potent inhibitors
were identiﬁed with marginal selectivity over the human
enzyme. There was little correlation between the enzyme
potency of these inhibitors and their cellular activity against
L. donovani axenic amastigotes, and this discrepancy could be due to poor cellular uptake due to the basicity of these
compounds. Thus, a series of analogues were synthesized with less basic centers. Although most of these compounds continued
to suﬀer from relatively poor antileishmanial activity, our most potent inhibitor of LmNMT (DDD100097, Ki of 0.34 nM)
showed modest activity against L. donovani intracellular amastigotes (EC50 of 2.4 μM) and maintained a modest therapeutic
window over the human enzyme. Two unbiased approaches, namely, screening against our cosmid-based overexpression library
and thermal proteome proﬁling (TPP), conﬁrm that DDD100097 (compound 2) acts on-target within parasites. Oral dosing
with compound 2 resulted in a 52% reduction in parasite burden in our mouse model of VL. Thus, NMT is now a
pharmacologically validated target in Leishmania. The challenge in ﬁnding drug candidates remains to identify alternative
strategies to address the drop-oﬀ in activity between enzyme inhibition and in vitro activity while maintaining suﬃcient
selectivity over the human enzyme, both issues that continue to plague studies in this area.
KEYWORDS: Leishmania, N-myristoyltransferase, thermal proteome proﬁling (TPP), drug discovery, target validation
Visceral leishmaniasis (VL), caused by infection with theprotozoan parasites Leishmania donovani and L. infantum,
is the second largest parasitic killer after malaria with more
than 200 million people currently at risk from infection. In
95% of cases, death can be prevented by timely and
appropriate drug therapy.1 However, current treatment options
are far from ideal with the best available therapies for VL being
miltefosine and liposomal amphotericin B (AmBisome).2 Both
drugs are superior to previous therapies such as pentavalent
antimonials,3 but they also have limitations. The principal
drawbacks of miltefosine are its teratogenicity, prolonged
treatment regimen, and high resistance potential.4 Problems
associated with amphotericin B include high treatment costs,
an intravenous route of administration, requirement for a cold
chain, and unresponsiveness in some Sudanese VL patients.5
Thus, there remains a deﬁnite and urgent need to strengthen
the range of treatment options for VL. Unfortunately, there are
currently no new therapeutics in clinical development and
relatively few in preclinical development2,6,7 (https://www.
dndi.org/diseases-projects/leishmaniasis/leish-portfolio/).
Drug discovery eﬀorts have been hampered by a paucity of
well-validated molecular drug targets in Leishmania, with the
molecular targets of the current clinically used drugs unknown.
As a result, drug discovery programs for VL have become
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heavily reliant upon whole cell (phenotypic) screening, despite
such screens suﬀering from extremely low hit rates.8
N-Myristoyltransferase (NMT, EC 2.3.1.97) remains one of
the very few robustly validated drug targets in the
Kinetoplastida. The enzyme catalyzes the co- and post-
translational addition of myristic acid (C14:0) onto the N-
terminal glycine of speciﬁc proteins.9,10 N-Myristoylation is
believed to play a crucial role in the correct cellular localization
and biological function of such modiﬁed proteins. NMT has
been extensively studied in a number of organisms including
humans, Trypanosoma brucei, T. cruzi, and Leishmania
spp.9,11−15 In these parasites, NMT has been demonstrated
as essential for viability either by classical gene knockout with
episomal rescue or by RNA interference, indicating that the N-
myristoylation of certain proteins is an essential biological
process. However, despite the development of numerous high
aﬃnity inhibitors capable of inhibiting the recombinant
enzyme in assays and selectively targeting NMT in cells,14−18
this enzyme has only been pharmacologically validated in the
African trypanosome, where DDD85646, a low nM inhibitor of
the enzyme, was able to cure a mouse model of stage one
African sleeping sickness.11 While it is tempting to assume that
NMT will be equally amenable to pharmacological inter-
vention in disease models of VL and Chagas’ disease, this is not
certain to be the case. T. brucei is acutely sensitive to NMT
inhibition, and this is largely attributed to the perturbation of
endocytosis, which occurs at exceptionally high rates in
bloodstream trypanosomes.19 Rates of endocytosis are likely
to be considerably slower in Leishmania20 and T. cruzi,21
raising the possibility that these parasites may be less
susceptible to inhibition of this biological process. Several
previous studies have reported that potent, tight binding
inhibitors of the L. major and T. cruzi NMT enzymes do not
translate as potent inhibitors of their respective parasites in
vitro.14,22 In the most comprehensive of these studies,22 Wright
and colleagues conﬁrm that two tight binding inhibitors are
capable of inhibiting N-myristoylation in L. donovani, providing
the ﬁrst direct evidence of on-target engagement with NMT in
this parasite. Indeed, this study demonstrates that the degree of
engagement of these inhibitors with NMT in Leishmania
parasites correlates directly with levels of cell killing.
Here, we describe the development of potent and selective
L. donovani NMT inhibitors. We use two unbiased method-
ologies to conﬁrm on-target activity in cells and, for the ﬁrst
time, demonstrate eﬃcacy of our lead compound in a mouse
model of VL. The implications of these ﬁndings for the
development of more potent and eﬃcacious NMT inhibitors
for the treatment of VL are discussed.
■ RESULTS AND DISCUSSION
Discovery. Previously, we reported a pyrazolyl sulfonamide
series that emerged from a high-throughput compound library
screen against Trypanosoma brucei N-myristoyltransferase
(TbNMT) (Figure 1, exempliﬁed by compound 1).11 As a
result of these studies, a number of potent NMT inhibitors
were developed including the lead compound DDD85646
which was curative in mouse models of stage 1 Human African
Trypanosomiasis (HAT). Unfortunately, this compound was
not active against the stage 2 HAT mouse model, where
parasites infect the central nervous system (CNS). This
treatment failure was attributed to poor penetration of the
blood−brain barrier, thus preventing therapeutic levels of
DDD85646 reaching the brain. To combat these issues, a
number of pyrazolyl sulfonamide analogues were developed
with the strategy of reducing polar surface area and capping the
sulphonamide to improve CNS penetration. This led to the
discovery of DDD100097 (Figure 1, compound 2) which was
a potent inhibitor of TbNMT and demonstrated moderate
eﬃcacy in the stage 2 mouse model.23
Compound 2 and other compounds synthesized in this
medicinal chemistry program were collated to form a focused
set of 1600 compounds selected for screening against L. major
NMT in a biochemical enzymatic assay. The format of this
384-well assay was broadly similar to that previously described
for TbNMT,11 with the same biotinylated CAP5.5 peptide
used as a substrate. Key aspects of the assay development are
summarized in Figure 2. The optimal enzyme concentration,
assay linearity with respect to time, and Michaelis constants for
CAP5.5 and myristoyl CoA were determined. The Km
app for
myristoyl CoA was determined to be 21 ± 4 nM and 1.0 ± 0.1
μM for CAP5.5 (Figure 2B,C). This assay returned a robust Z′
value of 0.7 ± 0.05 (n = 112) and successfully identiﬁed a
number of potent LmNMT inhibitors, with 130 compounds
inhibiting enzyme activity by >90% at 1 μM, a hit rate of 8.1%.
However, a counter-screen of these compounds against human
NMT revealed a pronounced lack of selectivity in most cases,
with a comparison of potencies demonstrating a strong
correlation (Figure 3A). The most potent inhibitors of
LmNMT were the methylpiperidine analogues 2 (N-diﬂuor-
omethylsulfonamide) and 3 (methylsulfonamide) with pIC50
values of 9.0 and 8.8, respectively (Figure 1 and Table 1), and
demonstrating ∼10-fold selectivity over the human enzyme.
The most promising LmNMT inhibitors were then screened
against L. donovani axenic amastigotes (extracellular, mamma-
lian stage). Unfortunately, there was little correlation between
enzyme inhibition and antileishmanial activity, with drop-oﬀs
in activity of up to 1000-fold commonly observed (Figure 3B).
Similar results have been reported elsewhere,17,22 where this
lack of translation was linked to both weak target engagement
and poor cellular uptake due to the presence of a basic
nitrogen that would be charged at physiological pH, thus
reducing cellular permeability.
In order to identify potential strategies to overcome this
issue, we interrogated a previously reported crystallographic
Figure 1. Chemical structures.
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structure of LmNMT with compound 1 bound in the active
site.23 The structure highlighted the water-mediated inter-
action of the piperidine nitrogen with the catalytic α-
carboxylate of the terminal leucine as being crucial for potency,
in agreement with previous studies.24 Therefore, a series of
analogues were designed and synthesized where the basic
piperidine was replaced with various heterocycles capable of
making this key interaction, but with a much less basic center
(Figure 1, compounds 4−9). Several of these analogues, where
the piperidine was replaced by pyrazoles (compounds 4−6), a
pyridine (compound 7), or an aniline (compound 8), retained
potency against LmNMT in the submicromolar range (Figure
1, Table 1). The poor activity of compound 9, where the
piperidine was replaced with a phenyl group incapable of
forming these key hydrogen bonds, again substantiated the
importance of the targeted carboxylate interaction.
Screening of this cohort of compounds against axenic
amastigotes again revealed a signiﬁcant drop-oﬀ in enzyme
Figure 2. LmNMT assay development. (A) Linearity of the assay with respect to enzyme concentration (data shown as mean CPM ± SD, n = 3).
(B) CAP5.5 Km determination (all data points shown, n = 2). (C) Myristoyl CoA Km determination (all data points shown, n = 3). (D) Assay
linearity with respect to time under the ﬁnal assay conditions of 5 nM LmNMT, 0.5 μM CAP5.5, and 125 nM myristoyl CoA (data shown as mean
CPM ± SD, n = 3).
Figure 3. Enzymatic and cellular eﬃcacy of LdNMT inhibitors. (A) Correlation of pIC50 values for a focused set of compounds against LmNMT
and HsNMT1 in enzymatic assays. Solid line represents equipotent activity while the dashed line represents a linear regression of the data (r2 =
0.856). (B) Correlation of potencies for a focused set of compounds against LmNMT (pIC50) in enzymatic assays versus L. donovani axenic
amastigotes (pEC50) cell-based assays. Solid line represents equipotent activity while the dashed line represents a linear regression of the data (r
2 =
0.358).
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versus cellular potency (50−430-fold), with the only exception
being the 3-pyridyl analogue (compound 7), where enzymatic
and antileishmanial activities were relatively similar (Table 1).
This characteristic drop-oﬀ in activity was even more
pronounced when compounds were screened against our
L. donovani intracellular amastigote assay.25 Indeed, only three
of the nine compounds tested demonstrated any activity
against these intracellular parasites at the concentrations tested,
with compound 2 being the most potent (EC50 value of 2.4 ±
0.8 μM). Interestingly, compound 2 also demonstrates
moderate activity against the intracellular amastigote form of
the related Kinetoplastid parasite T. cruzi (EC50 value of 0.47
μM compared with 5.1 μM against host Vero cells). Of
particular note, compound 7 returned an EC50 value of >50
μM despite showing submicromolar activity against axenic
amastigotes suggesting that the lack of translation between
enzyme and cellular potency is not driven solely by the eﬀect of
the basic nitrogen on cellular permeability potency.
On-Target Activity. The lack of correlation between our
enzyme and cell-based data could potentially be explained by
Table 1. Enzyme Inhibition and Cellular Data for NMT Inhibitors
compound ID abbreviation
LmNMT IC50,
μM
HsNMT IC50,
μM
promastigote
EC50, μM
axenic amastigote
EC50, μM
intramacrophage
EC50, μM
THP-1 EC50,
μM pKa
c
DDD99758 1 0.4 0.1 >50 >50 >50 >50 basic
DDD100097 2 0.0010a 0.01 0.04 ± 0.001 0.2 ± 0.006 2.4 ± 0.8 15.8 basic
DDD90146 3 0.0016b 0.02 0.07 ± 0.004 8.2 ± 0.6 7.1 ± 1.1 >50 basic
DDD101161 4 0.03 0.02 18.3 ± 0.1 2.7 ± 0.08 >50 >50 weakly
acidic
DDD101163 5 0.08 0.08 10.0 ± 0.4 9.2 ± 0.4 >50 >50 neutral
DDD101172 6 0.06 0.1 >50 >50 >50 >50 neutral
DDD101173 7 0.1 0.5 5.8 ± 0.4 0.3 ± 0.01 >50 >50 weakly
basic
DDD101177 8 0.03 0.008 8.2 ± 0.5 5.1 ± 0.2 >50 >50 neutral
DDD101169 9 10.0 6.3 6.3 ± 0.3 2.2 ± 0.03 40.5 ± 13.4 >50 neutral
aEstimated Ki value is 0.34 nM for this tight-binding inhibitor (see Materials and Methods).
bEstimated Ki value is 0.38 nM for this tight-binding
inhibitor (see Materials and Methods). cpKa values were calculated for each compound using the Jaguar pKa prediction component in the
Schrodinger Small molecule platform (Supplementary Table 1 and Supplementary Figure 1).
Figure 4. Target deconvolution utilizing a cosmid library approach. (A) Schematic representing the cosmid library workﬂow. (B) Cumulative
growth of cosmid library population treated with compound 2 (80 nM, closed circles) and untreated (open circles). (C) Genome-wide map
indicating cosmid library hits from screening of compound 2. A single primary hit was identiﬁed, indicated in blue. (D) Focus on primary “hit” on
chromosome 32. NMT (LdBPK_320080), green bar; other genes, black bars. The blue/pink and black/green peaks indicate independent cosmid
inserts in diﬀerent orientations. (E) Dose response curves of compound 2 against promastigotes constitutively overexpressing NMT (clone 1, black
circles; clone 2, gray circles) and WT promastigotes (open circles). Data are the mean ± SD of three technical replicates and are representative of
two independent experiments.
ACS Infectious Diseases Article
DOI: 10.1021/acsinfecdis.8b00226
ACS Infect. Dis. 2019, 5, 111−122
114
compounds drifting oﬀ-target within parasites. To address this
possibility, we used two unbiased approaches to identify the
speciﬁc molecular target(s) of our most promising compound
(compound 2) in L. donovani promastigotes. In the ﬁrst
instance, we screened this compound against our genome-wide
cosmid-based overexpression library (Figure 4). The principle
behind this approach is that overexpression of a drug target can
result in resistance to the corresponding drug by increasing the
pool of functional protein or by reducing free drug through
binding. The workﬂow for library construction and screening is
illustrated in Figure 4A. This high-coverage library was
constructed using a pcosTL cosmid backbone containing
fragments of Sau3AI partially digested genomic DNA (35−45
kb). The pooled cosmids were then transfected into
promastigotes. Prior to compound screening, cosmids
harbored by the transfected parasites were harvested and
analyzed by next generation sequencing. pcosTL-derived
“barcodes” were used to precisely map overexpressed frag-
ments to the reference Leishmania genome (LdBPK282A1).
This analysis conﬁrmed that our transfected library provided a
genome coverage of >15-fold and also that 99% of genes were
represented in the library.
Compound 2 was screened against the transfected library at
a concentration equivalent to 2× EC50 value (80 nM) (Figure
4B) until the growth of treated parasites was equivalent to that
of the untreated (12 days). Cosmids maintained by the
“resistant” population were harvested, sequenced and enriched
fragments were mapped to the L. donovani genome. This
screen revealed a single major hit on chromosome 32
comprising >44% of all mapped reads (Figure 4C, Supple-
mentary Table 2). No other notable hits were identiﬁed from
this screen. Closer inspection of this 50-kb region revealed 18
barcode pairs indicating that a mixed population of cosmid
fragments overlapping this area of the genome was enriched by
selection with this compound (Figure 4D). All enriched
cosmid fragments contained LdBPK_320080, the gene
encoding LdNMT, providing strong evidence that this enzyme
is the target of compound 2. Of the other genes in this region,
only LdBPK_320090.1 possessed a putative myristoylation
signal. This putative signal is also present in the orthologues of
other Leishmania species but absent in the T. brucei and
T. cruzi orthologues. Moreover, the possibility of
LdBPK_320090.1 conferring resistance by outcompeting
compound 2 in the active site of NMT seems unlikely,
particularly as this protein does not appear to be myristoylated
in whole cells.22 Finally, we conﬁrmed that overexpression of
NMT in L. donovani promastigotes results in an ∼10-fold
decrease in sensitivity to this pyrazolyl sulphonamide (Figure
4E).
Thermal proteome proﬁling (TPP) was used as an
additional approach to conﬁrm on-target engagement of
compound 2. TPP is based on the principle that binding of
a drug to its protein target can signiﬁcantly increase the
thermal stability of that protein.26 The workﬂow for our TPP
strategy is illustrated in Figure 5A. Brieﬂy, clariﬁed lysates of
L. donovani promastigotes were incubated in the presence of
compound 2 (10× established EC50 value) or DMSO vehicle.
Aliquots of lysate (drug and vehicle treated) were then
incubated at designated temperatures (between 34 and 61 °C),
and for each temperature, insoluble (denatured) proteins were
removed. The resulting soluble protein samples were reduced,
alkylated, and digested with trypsin prior to derivatization with
tandem mass tags (TMT). Pooled peptides were fractionated
by HPLC and analyzed by LC/MS-MS prior to identiﬁcation
and quantitation. The melting points of identiﬁed proteins
were then established using the TPP software package.
Two independent TPP experiments, each comprised of two
technical replicates, were carried out with compound 2 (0.4
μM). The top 25 proteins demonstrating thermal shift in the
presence of this compound from experiments 1 and 2 are
shown in Supplementary Tables 3 and 4. Of these, 7 proteins
from experiment 1 and 4 proteins from experiment 2 were
classiﬁed as legitimate “hits” or target candidates by the TPP
software package which applies strict selection criteria based on
Figure 5. Target deconvolution utilizing TPP. (A) Schematic representing our TPP workﬂow. TMT: tandem mass tags. (B) Venn diagram of
proteins identiﬁed as candidate targets of compound 2 from duplicate experiments (biological replicates). UniProt identiﬁers are used to represent
individual proteins. (C) Melting curves for L. donovani NMT following incubation with 0.4 μM compound 2 (red) or vehicle (0.1% DMSO, blue).
Data from two technical replicates (circles and squares) are shown, and the mean shift in melting temperature (ΔTm) for NMT was 3.3 °C. Data
from an independent duplicate experiment is presented in Supplementary Figure 2 and Supplementary Table 4.
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data quality (see Materials and Methods for details). The only
target candidate common to both data sets was LdNMT
(Figure 5B). Individual melting curves revealed that the
thermal stability of LdNMT increased by 3.3 °C (ΔTm) in
experiment 1 and 4.8 °C in experiment 2 (Figure 5C and
Supplementary Figure 2). It should be noted that TPP studies
provide evidence of on-target engagement rather than direct
evidence of inhibition of N-myristoylation. Nonetheless, these
ﬁndings support the results of our cosmid-based over-
expression library and the shift in potency observed with our
NMT-overexpressing cell line in conﬁrming LdNMT as the
molecular target of compound 2.
In Vivo Eﬃcacy of Compound 2. Despite a growing
number of studies describing medicinal chemistry strategies to
target Leishmania NMT,16,24,27−29 to the best of our
knowledge, none of the resulting compounds have been
reported as active in vivo. Thus, NMT remains to be
pharmacologically validated in Leishmania spp. This stage of
drug target validation is often overlooked but is one the most
robust since it addresses several key issues:30,31 ﬁrst, whether a
particular mode of action can have the required pharmaco-
logical response in an in vivo setting and, second, whether the
particular compound series has suitable pharmacokinetic
properties to address the target. Speciﬁcally, these studies
conﬁrm that a given target can be suﬃciently inhibited by
dosing of drug-like small molecules to elicit parasite death, in
the absence of host toxicity. With this in mind, compound 2
was selected for assessment in our mouse model of VL.6 The
selection of this compound for a proof-of-concept eﬃcacy
study was principally based not only on its promising potency
in intramacrophage assays but also on its previously
demonstrated oral bioavailability in mice.23 Oral dosing with
compound 2 at 50 mg kg−1 b.i.d. over 5 days resulted in a 52%
reduction in parasite burden (Figure 6), compared to vehicle
dosed control animals. This level of eﬃcacy is identical to that
seen with sodium stibogluconate sodium stibogluconate (52%
reduction), albeit with an increased dose and increased dosing
frequency, although some way short of the reduction of
parasite burden achieved with miltefosine (88% reduction).
Collectively, these data demonstrate NMT as a pharmacolog-
ically validated drug target in Leishmania for the ﬁrst time.
■ CONCLUSIONS
Target-based approaches to drug discovery for parasitic
diseases have proved problematic and are often plagued by
poor translation of enzyme activity to cellular potency and
ultimately in vivo eﬃcacy. NMT remains one of the very few
robustly validated drug targets in the kinetoplastids having
been conﬁrmed as genetically essential for the survival of
T. brucei, T. cruzi, and Leishmania spp. While potent inhibitors
of NMT in T. brucei have proved eﬀective in treating animal
models of stage 1 and 2 sleeping sickness, similarly potent
inhibitors developed against the Leishmania enzyme suﬀer
from considerable drop-oﬀs in activity against both axenic and
intracellular amastigotes. In this study, our strategy was to
reduce the basicity of inhibitors active against LmNMT with
the rationale that this was likely to improve cell permeability.
Unfortunately, this approach was not successful in improving
cellular potency, raising the possibility that this precipitous
drop in activity may be due to other factors. One possible
explanation is that Leishmania are simply less susceptible to
inhibition of NMT than other organisms. Alternatively, using
compounds similar to those described in our current study,
Wright and colleagues provided quantitative evidence that the
degree of inhibitor engagement with NMT in Leishmania
parasites correlates directly with cell killing, suggesting that the
drop-oﬀ in activity for this series may simply be due to weak
engagement with the target in the cell.22 We were able to
conﬁrm that our most promising compound acts on-target in
L. donovani using two unbiased orthogonal approaches and
that targeting of NMT can considerably reduce parasite burden
in vivo. Conﬁrmation of NMT as a pharmacologically validated
target in Leishmania is signiﬁcant. This study provides realistic
hope that future NMT inhibitors may prove curative in a VL
mouse model and have potential in a clinical setting. The
challenge remains to identify strategies to address the drop-oﬀ
in activity between enzyme inhibition and in vitro activity while
maintaining suﬃcient selectivity over the human enzyme.
Understanding the principal reasons for this drop-oﬀ in activity
will be crucial in informing our future chemical strategy:
whether this is due to permeability issues due to the charge of
the molecule or if signiﬁcantly more potent compounds are
required due to the lower susceptibility of Leishmania to
inhibition of NMT.
■ MATERIALS AND METHODS
General Chemistry. Chemicals and solvents were
purchased from Sigma-Aldrich, Alfa Aesar, Apollo Scientiﬁc,
Fluorochem, and TCI UK and were used as received. Air and
moisture sensitive reactions were carried out under an inert
atmosphere of nitrogen. Analytical thin-layer chromatography
(TLC) was performed using precoated TLC plates (layer of
0.20 mm silica gel 60 with ﬂuorescent indicator UV254, from
Merck). Developed plates were air-dried and analyzed under a
Figure 6. Eﬃcacy of compound 2 in a mouse model of VL. Eﬃcacy of
compound 2 was assessed at 50 mg kg−1 b.i.d. for 5 days, alongside
vehicle (orally administered b.i.d. for 5 days), miltefosine (orally
administered 30 mg kg−1 q.d. for 5 days), and sodium stibogluconate
(administered by subcutaneous injection at 15 mg kg−1 q.d. for 5
days). Each arm was carried out with 5 mice. Mean reduction in
parasite burden expressed as Leishman Donovan Units (LDU),
equivalent to the number of amastigotes per 500 nucleated cells
multiplied by the organ weight in milligrams. Treatment with
miltefosine resulted in an 88% reduction in liver parasite burden,
while dosing with both compound 2 and sodium stibogluconate
resulted in 52% reductions. Unpaired t tests conﬁrmed the reduction
in parasitaemia evident in all three groups of treated mice is
signiﬁcant, compared to untreated control animals, with P = 0.0021
(*), P < 0.0001 (***), and P = 0.0009 (**) for sodium
stibogluconate, miltefosine, and compound 2, respectively.
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UV lamp (UV254/365 nm) and/or with chemical stains where
appropriate. Flash column chromatography was performed
using prepacked silica gel cartridges (230−400 mesh, 35−70
μm, from Teledyne ISCO) using a Teledyne ISCO
CombiFlash Rf. 1H NMR were recorded on a Bruker Avance
DPX 500 spectrometer (at 500.1 MHz), a Bruker Avance III
HD (at 400.1 MHz), or a Bruker Avance DPX 300 (at 299.9
MHz). Chemical shifts (δ) are expressed in ppm recorded
using the residual solvent as the internal reference in all cases.
Signal splitting patterns are described as singlet (s), doublet
(d), triplet (t), quartet (q), multiplet (m), broad (br), or a
combination thereof. LC-MS analyses were performed with
either an Agilent HPLC 1100 series connected to a Bruker
Daltonics MicrOTOF or an Agilent Technologies 1200 series
HPLC connected to an Agilent Technologies 6130 quadrupole
LC/MS, where both instruments were connected to an Agilent
diode array detector and all ﬁnal compounds were >95%
purity. LCMS chromatographic separations were conducted
with either a Waters XBridge C18 column, 50 mm × 2.1 mm,
3.5 μm particle size, or Waters XSelect C18 column, 30 mm ×
2.1 mm, 2.5 μm particle size; mobile phase was water/
acetonitrile + 0.1% HCOOH or water/acetonitrile + 0.1%
NH3. Preparative HPLC separations were performed with a
Waters mass-directed HPLC (system ﬂuidics organizer, 2545
binary gradient module, 2 × 515 HPLC pumps, 2767 sample
manager) connected in parallel to a Waters 3100 mass detector
and a 2998 photodiode array detector.
2,6-Dichloro-N-methyl-4-(piperazin-1-yl)-N-(1,3,5-tri-
methyl-1H-pyrazol-4-yl)benzenesulfonamide. A mixture
of 4-bromo-2,6-dichloro-N-methyl-N-(1,3,5-trimethyl-1H-pyr-
azol-4-yl)benzenesulfonamide23 (2.12 g, 5 mmol), cesium
carbonate (3.26 g, 10 mmol), xantphos (288 mg, 0.5 mmol),
and tris(dibenzylideneacetone)dipalladium(0) (228 mg, 0.25
mmol) in 1,4-dioxane (25 mL) was degassed and stirred at 65
°C overnight. After cooling, water (100 mL) and DCM (100
mL) were added and the organic layer was separated,
evaporated, and puriﬁed by ﬂash chromatography (10−100%
EtOAc/heptane) to give the Boc-protected intermediate. This
was taken up in DCM (5 mL)/TFA (5 mL) and stirred for 2 h.
Solvent was evaporated, and crude material was dissolved in
methanol, loaded onto an SCX column, and eluted with 2 M
NH3/MeOH. Solvent was evaporated to give product which
was used without further puriﬁcation (590 mg, 1.37 mmol,
27%). 1H NMR (CDCl3): δ 6.80 (s, 2H), 3.69 (s, 3H), 3.38 (s,
3H), 3.30−3.26 (m, 4H), 3.03−2.98 (m, 4H), 2.15 (s, 3H),
1.87 (s, 3H).
4-(4-(1H-Pyrazole-5-carbonyl)piperazin-1-yl)-2,6-di-
chloro-N-methyl-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-
benzenesulfonamide (Compound 4). A solution of 2,6-
dichloro-N-methyl-4-(piperazin-1-yl)-N-(1,3,5-trimethyl-1H-
pyrazol-4-yl)benzenesulfonamide (80 mg, 0.19 mmol), TBTU
(77 mg, 0.25 mmol), and DIPEA (75 μL, 4.4 mmol) was
stirred for 5 min; 1H-pyrazole-5-carboxylic acid (25 mg, 0.23
mmol) was added and stirred for 4 h. The crude solution was
puriﬁed directly by mass-directed HPLC to give 4 (35 mg,
0.067 mmol, 35%). 1H NMR (CDCl3): δ 7.65 (d, J = 2.4 Hz,
1H), 6.82 (m, 3H), 4.23−3.96 (m, 4H), 3.69 (s, 3H), 3.53−
3.41 (m, 4H), 3.39 (s, 3H), 2.15 (s, 3H), 1.86 (s, 3H). MS
(ESI): m/z 526.2, 528.2 [M + H]+.
2,6-Dichloro-N-methyl-4-(4-(1-methyl-1H-pyrazole-4-
carbonyl)piperazin-1-yl)-N-(1,3,5-trimethyl-1H-pyrazol-
4-yl)benzenesulfonamide (Compound 5). Compound 5
was synthesized by an analogous method to 4 using 1-methyl-
1H-pyrazole-4-carboxylic acid (28 mg, 0.23 mmol) to give 23
mg (0.042 mmol, 22% yield). 1H NMR (CDCl3): δ 7.77 (s,
1H), 7.66−7.65 (m, 1H), 6.81 (s, 2H), 3.96 (s, 3H), 3.91−
3.88 (m, 4H), 3.68 (s, 3H), 3.44−3.40 (m, 4H), 3.39 (s, 3H),
2.16 (s, 3H), 1.86 (s, 3H). MS (ESI): 540.2, 542.2 [M + H]+.
4-(4-(1H-Pyrazole-4-carbonyl)piperazin-1-yl)-2,6-di-
chloro-N-methyl-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-
benzenesulfonamide (Compound 6). Compound 6 was
synthesized by an analogous method to 4 using 1H-pyrazole-4-
carboxylic acid (25 mg, 0.23 mmol) to give 29 mg (0.055
mmol, 29% yield). 1H NMR (CDCl3): δ 7.90 (s, 2H), 6.81 (s,
2H), 3.94−3.89 (m, 4H), 3.69 (s, 3H), 3.45−3.40 (m, 4H),
3.39 (s, 3H), 2.15 (s, 3H), 1.86 (s, 3H). MS (ESI): m/z 526.2,
528.2 [M + H]+.
2,6-Dichloro-N-methyl-4-(4-nicotinoylpiperazin-1-yl)-
N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
(Compound 7). Compound 7 was synthesized by an
analogous method to 4 using nicotinic acid (27 mg, 0.23
mmol) to give 22 mg (0.041 mmol, 22% yield). 1H NMR
(CDCl3): δ 8.75−8.73 (m, 2H), 7.84−7.81 (m, 1H), 7.45−
7.41 (m, 1H), 6.83 (s, 2H), 3.99−3.77 (m, 4H), 3.69 (s, 3H),
3.47−3.33 (m, 7H), 2.17 (s, 3H), 1.85 (s, 3H). MS (ESI): m/z
537.2, 539.2 [M + H]+.
4-(4-(4-Aminobenzoyl)piperazin-1-yl)-2,6-dichloro-N-
methy l -N - ( 1 , 3 ,5 - t r imethy l - 1H -py razo l -4 -y l ) -
benzenesulfonamide (Compound 8). Compound 8 was
synthesized by an analogous method to 4 using 4-amino-
benzoic acid (31 mg, 0.23 mmol) to give 30 mg (0.054 mmol,
28% yield). 1H NMR (DMSO): δ 7.18 (d, J = 8.6 Hz, 2H),
7.04 (s, 2H), 6.57 (d, J = 8.6 Hz, 2H), 5.56 (bs, 2H), 3.62−
3.57 (m, 7H), 3.47−3.43 (m, 4H), 3.25 (s, 3H), 1.96 (s, 3H),
1.79 (s, 3H). MS (ESI): m/z 551.2. 553.2 [M + H]+.
2,6-Dichloro-N-methyl-4-(4-(2-phenylacetyl)-
piperazin-1-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-
benzenesulfonamide (Compound 9). Compound 9 was
synthesized by an analogous method to 4 using phenylacetic
acid (30 mg, 0.23 mmol) to give 33 mg (0.060 mmol, 32%
yield). 1H NMR (CDCl3): δ 7.39−7.27 (m, 5H), 6.75 (s, 2H),
3.83−3.79 (m, 4H), 3.69 (s, 3H), 3.63−3.59 (m, 2H), 3.38 (s,
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3H), 3.34−3.30 (m, 2H), 3.15−3.11 (m, 2H), 2.16 (s, 3H),
1.85 (s, 3H). MS (ESI): m/z 550.2, 552.2 [M + H]+.
Jaguar pKa Predictions. pKa values for the desired sites in
compounds 1−9 were calculated by ab initio quantum
mechanics using the Jaguar pKa prediction component in the
Schrodinger Small molecule platform (Schrödinger Release
2018-2: Jaguar, Schrödinger, LLC, New York, NY, 2018).32
The Jaguar pKa prediction module calculates the pKa (or pKb)
of molecules that contain acidic or basic functional groups.
The calculations involve geometry optimization of the ionic
and neutral species and single-point energy and frequency
calculations using the Self Consistent Field (SCF) method,
plus an empirical correction. For each compound, a thorough
conformational search was carried out and the 5 lowest energy
conformers (within 12 kcal mol−1) were used for pKa
calculation using water as solvent. Default parameters were
used for SCF convergence. Diﬀerent pseudospectral grid cut-
oﬀs were used for each compound, and results were averaged.
LmNMT Recombinant Protein Expression and Puriﬁ-
cation. Recombinant LmNMT was expressed and puriﬁed as
previously described.33
LmNMT Enzymatic Assay. LmNMT assays were carried
out at room temperature (22−23 °C) in 384-well white
optiplates (PerkinElmer). Each assay was performed in a 40 μL
reaction volume containing 30 mM Tris, pH 7.4, 0.5 mM
EDTA, 0.5 mM EGTA, 1.25 mM dithiothreitol (DTT), 0.1%
(v/v) Triton X-100, 0.125 μM [3H]myristoyl-CoA (8 Ci
mmol−1) (PerkinElmer), 0.5 μM biotinylated CAP5.5 peptide
substrate (GCGGSKVKPQPPQA[K-Biotin]) (Pepceuticals),
5 nM LmNMT, and various concentrations of the test
compound.
Test compound (0.4 μL in DMSO, ﬁnal concentration of 1
μM) was transferred to all assay plates using a Cartesian
Hummingbird (Genomics Solution) before 20 μL of enzyme
was added to assay plates (with buﬀer only added to “no
enzyme” control wells). The reaction was initiated with 20 μL
of a substrate mix and stopped after 30 min with 40 μL of a
stop solution containing 0.2 M phosphoric acid, pH 4.0, 1.5 M
MgCl2, and 1 mg mL
−1 PVT SPA beads (GE Healthcare). All
reaction mix additions were carried out using a Thermo
Scientiﬁc WellMate (Matrix). Plates were sealed and read on a
TopCount NXT Microplate Scintillation and Luminescence
Counter (PerkinElmer).
ActivityBase from IDBS was used for data processing and
analysis. All IC50 curve ﬁtting was undertaken using XLFit
version 4.2 from IDBS. A four-parameter logistic dose−
response curve was used using XLFit 4.2 Model 205. All test
compound curves had ﬂoating top and bottom, and preﬁt was
used for all four parameters.
Ki Calculations. Ki values were calculated for compounds 2
and 3, identiﬁed as tight binding inhibitors in our enzyme
inhibition assays.34 The nominal concentration of NMT in
these assays was 5 nM. Fitting the data to the IC50 equation
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yielded a value of 1.17 ± 0.07 nM for compound 2, indicating
that tight-binding inhibition was operative, since the lowest
possible IC50 value is half of the total active enzyme
concentration (i.e., 2.5 nM).
Accordingly, these data were ﬁtted to Morrison’s quadratic
equation for tight-binding inhibitors
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where vi/v0 is the fractional activity in the presence of inhibitor,
ET and IT are the total concentrations of enzyme and inhibitor
in the assay, and Ki
app is the apparent inhibition constant. This
equation will ﬁt all IC50 data, provided the concentration of
active enzyme is accurately known. Fitting by nonlinear
regression with ET as a variable returned an active enzyme
concentration with a high error. Linear regression of the lowest
inhibitor concentrations was used to obtain a more accurate
estimate of the concentration of active enzyme. This yielded an
estimate of 1.56 nM active NMT (correlation coeﬃcient of
0.966). Using this value as a ﬁxed parameter in the above
equation yielded a Ki
app = 0.51 ± 0.08 nM (for compound 2).
For a competitive inhibitor,
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Substituting [S] = 0.5 μM and Km = 1.0 μM into the Cheng-
Prusoﬀ equation yields a Ki value of 0.34 nM for compound 2.
The Ki value of compound 3 was calculated in an identical
manner.
Cell Lines and Culture Conditions. The clonal
L. donovani cell line LdBOB (derived from MHOM/SD/62/
1S-CL2D) was used in our in vitro compound screening and
mechanism of action studies. Promastigotes were grown at 26
°C in modiﬁed M199 media with axenic amastigotes grown at
37 °C, as previously described.35 All animal studies were
carried using L. donovani (LV9; WHO designation: MHOM/
ET/67/HU3).
L. donovani Intramacrophage, Axenic Amastigote,
and Promastigote Compound Sensitivity Assays. These
assays were carried out as previously described.25,36,37
In Vivo Eﬃcacy. Groups of female BALB/c mice (5 per
group) were inoculated intravenously with approximately 2 ×
107 L. donovani amastigotes (LV9) harvested from the spleen
of an infected hamster.38 From day 7 postinfection, groups of
mice were treated with drug vehicle only (orally), with
miltefosine (30 mg kg−1 orally), with sodium stibogluconate
(15 mg kg−1 subcutaneously), or with compound 2 (50 mg
kg−1 orally). Miltefosine and sodium stibogluconate were
dosed once daily for 5 days while compound 2 was dosed twice
daily for 5 days. Dosing solutions were prepared fresh each
day, and the vehicle used was Milli-Q H2O (miltefosine and
sodium stibogluconate) and 10% DMSO/60% PEG400/30%
Milli-Q H2O (compound 2). On day 14 (5 days dosing
groups), all animals were humanely euthanized; liver smears
were made, and parasite burdens were determined by counting
the number of amastigotes/500 liver cells.37 Parasite burden is
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expressed in Leishman Donovan Units (LDU): mean number
of amastigotes per 500 liver cells × mg weight of liver.39
Ethical Statement. All regulated procedures, at the
University of Dundee, on living animals were carried out
under the authority of a project license issued by the Home
Oﬃce under the Animals (Scientiﬁc Procedures) Act 1986, as
amended in 2012 (and in compliance with EU Directive EU/
2010/63). License applications are approved by the Uni-
versity’s Ethical Review Committee (ERC) before submission
to the Home Oﬃce. The ERC has a general remit to develop
and oversee policy on all aspects of the use of animals on
University premises and is a subcommittee of the University
Court, its highest governing body.
Cosmid Library Generation. The cosmid backbone
pcosTL40 was a kind gift from John Kelly (London School
of Hygiene and Tropical Medicine). The library was
constructed essentially as described previously.41 Brieﬂy,
pcosTL was digested sequentially with SmaI and BamHI.
The digested cosmid was then ligated with size-selected
Sau3AI partial digest products of L. donovani (strain 1SR)
genomic DNA. After packaging, using the Gigapack Gold II kit
(Stratagene), the complexity of the library was tested and the
library was ampliﬁed and stored at −70 °C. Mid-log L. donovani
promastigotes (4 × 107 cells per transfection) were transfected
with 10 μg of cosmid library DNA. Promastigotes maintaining
cosmids were selected by the addition of G418 (125 μg mL−1)
to the culture medium. Parasites recovered from 36 trans-
fections were pooled to build the ﬁnal cosmid library. In total,
90 000 integrated genomic DNA fragments were recovered
from our Leishmania library suggesting a ﬁnal genome coverage
of ∼15-fold.
Cosmid Library Screening. Cosmid-containing L. donova-
ni promastigotes were maintained at a minimum concentration
of 1 × 105 cells mL−1 (1.5 × 107 cells in total). Test
compounds were added to the library at an initial
concentration equivalent to 2× their established EC50 values.
Cell densities were monitored daily, and the library was
subcultured before reaching 1 × 107 mL−1, with addition of
fresh test compound. In cases where the addition of test
compounds (2× EC50) had no impact on cell growth, higher
concentrations were added. Libraries were continuously
cultured in the presence of test compounds until there was a
marked increase in cell growth suggesting the emergence of a
selected, resistant promastigote population. Genomic DNA
and accompanying cosmids were isolated from selected
L. donovani promastigotes (1.5 × 109 cells in total) using a
standard alkaline lysis protocol. The resulting DNA was
transformed into ElectroMAX DH5α-E cells, and the resultant
transformants (containing cosmids) were puriﬁed using a
NucleoBond Xtra Midi Plus kit (Machery-Nagel).
Sequencing of Selected Cosmids. Puriﬁed cosmid DNA
was sequenced using an Illumina HiSeq platform (Beijing
Genomics Institute). Sequence reads were aligned to the
L. donovani BPK282A1 genome sequence (v9.0, tritrypdb.org)
using Bowtie2 software42 with the following conditions: very-
sensitive-local. The aligned ﬁles were then manipulated using
SAMtools43 and a custom python script44 to identify reads
with barcodes (CTCTTAAAAGCATCATGTCT and
AGACATGATGCTTTTAAGAG). Reads were then quanti-
ﬁed using the Artemis genome browser45 and Excel.
Generation of L. donovani Cell Line Overexpressing
LdNMT. The NMT gene was ampliﬁed from L. donovani
(LdBOB) genomic DNA using primers LdNMTbglIIFW
(GATCAGATCTATGTCTCGCAATCCATCGAACT) and
LdNMTbglIIRV (GATCAGATCTCTACAACATCACC-
AAGGCAACC) with gene-speciﬁc sequences ﬂanked by
BgIII sites (underlined). This resulting ampliﬁed fragment
was digested with BglII prior to ligation into the similarly
digested pIR1-SAT vector (a kind gift from Professor Steve
Beverley). The validity of the construct was conﬁrmed by
sequencing. The resulting construct was digested with SwaI
and transfected into L. donovani promastigotes. Transfected
parasites were selected and maintained by selection with
nourseothricin (100 μg mL−1).
Quantitative RT-PCR. RNA was harvested from mid-log
L. donovani promastigotes (1 × 108) using the RNeasy Mini
Kit (Qiagen) and used to synthesize cDNA using an RNA-to-
cDNA kit (Applied Biosystems), as per the manufacturers’
instructions. Quantitative RT-PCR reactions were performed
using Brilliant III Ultra-Fast QPCR Master Mix (Agilent
Technologies) with the following cycling conditions: 95 °C for
3 min (1 cycle), 95 °C for 20 s, and 60 °C for 20 s (40 cycles).
Relative quantiﬁcation was established using the reference
gene, rRNA45.46 The level of NMT in the overexpression cell
lines was normalized to wildtype using the ΔΔCt method. Two
independently transfected clones were used, and signiﬁcance
was measured using a student’s unpaired t test.
L. donovani Lysate Preparation. L. donovani (LdBOB)
promastigotes were grown in large scale roller bottle cultures
starting at an initial concentration of 1 × 105 cells mL−1 (1.5 ×
107 cells in total). Cell were grown for 72 h, as previously
described. Promastigotes were harvested by centrifugation
(1912g, 15 min, 4 °C) and washed with ice-cold PBS (1912g, 5
min, 4 °C), and ﬁnally, the cell pellet was resuspended in 8 mL
of ice-cold lysis buﬀer (1 mM EDTA, 1 mM DTT, 100 μM
TLCK, and 1× Roche EDTA-free cOmplete protease inhibitor
cocktail in 50 mM potassium phosphate buﬀer, pH 7.4). The
cell suspension was submitted to 3 freeze−thaw cycles in a dry
ice/ethanol bath to biologically inactivate the parasites and
then submitted to cell disruption (Constant Systems, UK) at
30 kpsi. The resulting lysate was centrifuged (100 000g, 20
min, 4 °C); supernatant was collected, and the protein
concentration was determined using the Bio-Rad Protein
Assay.
Thermal Shift Assays. The lysate concentration was
adjusted to 2.5 mg mL−1 with lysis buﬀer, and then, 2 × 2 mL
aliquots were incubated at room temperature for 30 min in the
presence of test compound (equivalent to 10× EC50) or
vehicle (0.1% DMSO). Each 2 mL aliquot (drug and vehicle
treated) was divided into 10 × 100 μL aliquots in 0.5 mL thin-
walled PCR tubes and incubated at a designated temperature
(34, 37, 40, 43, 46, 49, 52, 55, 58, or 61 °C) for 3 min followed
by incubation at RT for 3 min before each sample was placed
on ice. Each aliquot was centrifuged (100 000g, 20 min, 4 °C);
supernatants were collected, and the protein concentration was
assessed.
Sample Processing. Samples were reduced by the
addition of TCEP (25 mM ﬁnal concentration) and incubated
at 37 °C for 10 min. Alkylation was carried out by the addition
of iodoacetamide (25 mM ﬁnal concentration) and incubated
at RT for 1 h in the dark. Samples were then digested by the
addition of 1:50 LysC (Wako, Japan) in 100 mM
triethylammonium bicarbonate (TEAB) followed by incuba-
tion at 37 °C for 6 h and then addition of 1:50 trypsin
(Thermo) followed by incubation at 37 °C overnight. The
eﬃciency of sample digestion eﬃciency was assessed by LC-
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MS/MS (LTQ XL, Thermo). The samples were then vacuum-
dried and resuspended in 100 mM TEAB (100 μL). Samples
were then incubated in their respective tandem mass tag
(TMT) 10-plex reagents (Thermo) for 1 h at RT with
agitation. Reactions were quenched by the addition of 5%
hydroxylamine for 15 min, and each set of samples (treated
and vehicle) was pooled in the same tube and dried overnight.
The TMT-labeled samples were dried and kept at −85 °C until
further analysis.
Fractionation by HPLC. Pooled samples were resus-
pended in 200 μL of 10 mM ammonium formate (pH 9.5) and
fractionated by high-pH reversed phase HPLC. A C18 column
(XBridge peptide BEH, 130 Å, 3.5 μm, 2.1 × 150 mm, Waters)
with a guard column (XBridge, C18, 3.5 μm, 2.1 × 10 mm,
Waters) was used on an Ultimate 3000 HPLC (Thermo-
Scientiﬁc). Ammonium formate (100 mM) was adjusted to pH
9.5 with ammonia and used to prepare buﬀer A (10 mM
ammonium formate in Milli-Q water) and buﬀer B (10 mM
ammonium formate, 90% acetonitrile). The column and guard
column were equilibrated with 2% buﬀer B for 20 min at a
constant ﬂow rate of 0.2 mL min−1 for 20 min. Samples (180
μL) were loaded onto the column at 0.2 mL min−1, and a
separation gradient started 1 min after samples were loaded
onto the column. Peptides were eluted from the column with a
gradient of 2% buﬀer B to 20% B over 8 min then from 20% B
to 47% B over 37 min. The column was then washed for 15
min with 100% buﬀer B. Fractions were collected from 1 to 80
min using a WPS-3000FC autosampler (Thermo-Scientiﬁc) at
1 min intervals. Fractions were pooled to give 20 pools of
approximately equivalent peptide content (as judged by UV
trace at 220 nm), dried in a Speedvac, and dissolved in 50 μL
of 1% formic acid prior to analysis by LC-MS/MS.
LC-MS/MS. Analysis of peptides was performed on a Q-
Exactive-HF (Thermo Scientiﬁc) mass spectrometer coupled
to a Dionex Ultimate 3000 RS (Thermo Scientiﬁc). LC buﬀers
used were as follows: buﬀer A (0.1% formic acid in Milli-Q
water (v/v)) and buﬀer B (80% acetonitrile and 0.08% formic
acid in Milli-Q water (v/v)). Aliquots of each sample (1 μL)
were loaded at 5 μL·min−1 onto a trap column (100 μm × 2
cm, PepMap nanoViper C18 column, 5 μm, 100 Å, Thermo
Scientiﬁc) equilibrated in 5% buﬀer B. The trap column was
washed for 5 min at the same ﬂow rate and then switched in-
line with a Thermo Scientiﬁc resolving C18 column (75 μm ×
50 cm, PepMap RSLC C18 column, 2 μm, 100 Å). Peptides
were eluted from the column at a constant ﬂow rate of 300 nL
min−1 with a linear gradient from 5% buﬀer B (for pools 1−
10) or 7% buﬀer B (for pools 11−20) to 35% buﬀer B over
130 min and then to 98% buﬀer B over 2 min. The column was
then washed with 98% buﬀer B for 20 min and re-equilibrated
in 5% buﬀer B for 17 min. The Q-exactive HF was used in
data-dependent mode. A scan cycle comprised MS1 scan (m/z
range from 335 to 1800, with a maximum ion injection time of
50 ms, a resolution of 120 000, and automatic gain control
(AGC) value of 3 × 106) followed by 15 sequential dependent
MS2 scans (with an isolation window set to 0.7 Da, resolution
at 60 000, maximum ion injection time at 200 ms, and AGC of
1 × 105). To ensure mass accuracy, the mass spectrometer was
calibrated immediately prior to analysis of the 20 fraction
pools.
Peptide and Protein Identiﬁcation and Quantitation.
MS data were analyzed using the software MaxQuant (http://
maxquant.org/, version 1.6.1.0). Carbamidomethyl (C),
oxidation (M), acetyl (Protein N-term), deamidation (NQ),
and Gln→ pyro-Glu were set as variable-modiﬁcations.
Proteins were identiﬁed by searching the MS and MS/MS
data for the peptides against L. donovani strain BPK282A1
(UniProt Protein Knowledgebase). Trypsin/P and LysC/P
were selected as the digestive enzyme with two potential
missed cleavages. Reporter ion MS2 mode was selected using
the TMT-10plex labels on N-termini and lysine epsilon-amino
groups. Protein abundance was calculated according to the
normalized reporter ion intensities. The FDR threshold for
peptides and proteins was 0.01. FTMS MS/MS mass tolerance
was set to 10 ppm, and ITMS MS/MS mass tolerance was 0.06
Da.
Thermal Proteome Proﬁling (TPP) Data Analysis. TPP
experiments were analyzed using the TPP Package available in
Bioconductor, as previously described.47 Brieﬂy, the MaxQuant
protein group ﬁle was used to extract the raw protein
abundance (reporter intensity corrected columns). Contami-
nant protein groups (e.g., non-L. donovani proteins), reverse
sequence identiﬁcations, and “only identiﬁed by site hits” were
removed from this list. TMT quantiﬁcation was scaled by
dividing each protein time point series by the intensity of the
lowest temperature reporter (34 °C). The melting curves were
calculated using a sigmoidal ﬁtting approach with the R
package TPP. This ﬁtting was used to determine the melting
point (Tm), which is deﬁned as the temperature at which half
of the amount of proteins was denatured. The melting point
diﬀerences (ΔTm) were calculated by subtracting the Tm values
of treated and untreated samples. The sigmoidal melting curves
were ﬁltered according to the following criteria: melting curves
must reach a relative abundance plateau of < 0.3, and the
coeﬃcient of determination (r2) must be >0.8. The statistical
signiﬁcance was calculated by using the nonparametric analysis
of response curves (NPARC) of the R package TPP. The
signiﬁcance threshold was set to P < 0.05. All proteomics data
sets have been deposited with the PRoteomics IDEntiﬁcations
(PRIDE) database.
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